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Background and Aim 
Glycated hemoglobin (HbA1c) plays a crucial role in the monitoring and diagnosis 
of diabetes. In Portugal 9,8% of the population  has diabetes (HbA1c ≥ 6,5%  or 
treatment with glucose-lowering medications)1. Six sigma metrics combine bias, 
precision, and allowable total error (Tea), and can be used for assessing the 
quality of the analytic phase. 
The main objective of this study was to apply a linear regression model for long-
term evaluation of the precision and inaccuracy, and apply the sigma metric to 
evaluate the performance of laboratories in HbA1c quantification
2. 
Methods 
The long term analytical coefficient of variation (LCVa), the total analytical bias 
and sigma were established.  
Participants were  selected concerning laboratories  that participated in all 
surveys. The assessment did not take into account the equipment used by each 
participant. The variables introduced to define the long-term performance in this 
model were the LCVa and total analytical Bias obtained by comparing the 
laboratory individual results with the consensus mean of each round, after 
outliers exclusion. The sigma value was calculate using the Tea obtained in the 
minimums analytical performance goals based on the biological variation3,4. A 
linear regression model was applied to quantitative HbA1c results, of twelve 
EDTA blood samples with different HbA1c concentrations, to evaluate the long-
term analytical performance and the sigma value of twenty one participants in 
the period of 2014 to 2016 that participate in the PNAEQ (External Quality 
Assessment Program). Results are expressed in IFCC units (mmol/mol). Four 
laboratories were excluded from the analysis (outliers). We evaluate also the 
number of laboratories that fulfill the minimum analytical performance goals 
based on the biological variation (CVa and Bias).  
Results 
The consensus values, interlaboratory CV and number of outliers for the 12 surveys/samples used in the study are represented in table 1. The 
median LCVa was 2,4% (range 1,3%-5,2%), the median Total Bias was 2,0% (range 0,2%-6,0%) and median sigma value was 1,7 (range 0,1-
4,6) (table 2).  
The LCVa was less than 0,58 times the total biological variation (diagnostic testing) for 94 % laboratories and was less than 0,75 times the within 
biological variation (monitoring testing) in 29 % of the laboratories. Sixty five percent of the laboratories had a total bias less than 0,375 of the 
total biological variation (table 3). 
Forty one percent of the laboratories had a sigma value less than 2,0 and fifty nine percent had a sigma value equal or higher than 2,0, when 
evaluated with an allowable total error of 6,72%, based on minimum performance criterions of the biological variation (figure 1).  
Table 1: Consensus values, interlaboratory CV and number 
of outliers for the 12 surveys/samples used in the study 
Survey/ 
Sample  
No. of 
participants  
Consensus 
value, 
mmol/mol 
CV, %  
No. of 
outliers  
2116 38 99,7 4,72 1 
2216 38 34,7 6,33 2 
1116 44 59,6 4,16 2 
3216 37 37,9 4,95 2 
3115 52 95,7 5,37 1 
3215 51 33,9 6,13 2 
2115 55 101,1 4,38 1 
3116 37 94,6 7,51 2 
1115 51 82,7 4,37 2 
1215 51 60,7 4,72 1 
3114 53 85,0 2,62 12 
3214 53 31,0 2,39 11 
Table 2: Descriptive analysis of Long-term analytical CV, 
total Bias and Sigma value results  
   LCVa, %  Bias,  %  
Sigma 
(Tea=6,72%) 
Median  2,4 2,0 1,7 
Range  1,3-5,2 0,2-6,0 0,1-4,6 
n  17 17 17 
Table 3: “Minimum” performance goals and quality specifications for Glycated Haemoglobin. [CVt – Total biologic variation; Cvi – Within 
subject variation; CVb – Between suject variation] and percentage of laboratories in the study within the minimum performance goals 
   
“Minimum” Performance goals  Quality specifications  Laboratories within the Minimum 
performance goals, %  HbA1c mmol/L HbA1c mmol/L 
Imprecision (Diagnostic) %  0,58 CVt ( √(CVi2   + CVb2)) 5,09 94 
Imprecision (Monitoring ) %  0,75 CVb within 2,08 29 
Total Bias%  0,375 √(CVi2   + CVb2) 2,52 65 
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% of laboratories 
Sigma < 2 41 
Sigma ≥ 2 59 
Figure 1: : Histogram of the individual  Sigma for Glycated 
haemoglobin for the 17 laboratories included in the study and the 
percentage of laboratories with sigma value inferior to 2 and 
superior or equal to 2. 
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As reflected by the results the overall performance needs to be improved. Despite 94% of the laboratories evaluated accomplished the minimum 
quality specifications for imprecision (diagnostic), only 65% and 29% of the laboratories met the quality specifications for Total Bias and imprecision 
(monitoring) respectively. The median sigma (1.7) was less than 2 and only 59% of the laboratories had a sigma greater than or equal to 2. 
It is a responsibility of clinical laboratories to continuously monitor the performance of the methods in use, both by the implementation of proper 
internal quality control, checking the daily alignment of the analytical system and evaluating the assay long-term imprecision by the participation in 
appropriately organized external quality assessment schemes. 
Assessment of the quality on the sigma scale has the advantage of providing evidence of global laboratory performance taking into account random 
and systematic errors, and should be used for identifying and prioritizing improvements that are needed in the analytical quality of laboratory 
examinations. 
Conclusion 
